摘要
目的探讨宫颈癌新辅助化疗前后P-gp、MRP1和GST-π的表达及其与化疗疗效的关系。方法运用S-P法检测30宫颈鳞癌新辅助化疗前后P-gp、MRP1和GST-π的表达水平。结果①化疗后宫颈鳞癌组织中P-gp阳性表达率为83.3%,显著高于化疗前55.5%(P<0.05);化疗前P-gp阴性患者有效率为100%显著高于P-gp表达阳性患者有效率64.1%(P<0.05)。②化疗后宫颈鳞癌组织中GST-π阳性表达率为83.3%,显著高于化疗前60%(P<0.05);化疗前P-gp阴性患者有效率为83.3%显著高于P-gp表达阳性患者有效率66.7%(P<0.05)。③化疗前后宫颈鳞癌组织中MRP1阳性表达率分别为为86.7%和93.3%,二者间无显著性差异(P>0.05);化疗前P-gp阴性、阳性患者有效率分别为100%和76.9%,二者间无显著性差异(P>0.05)。结论P-pg和GST-π可作为预测宫颈鳞癌化疗敏感性指标。
Objective To investigate the expression of P-gp, MRP1 and GST-π in cervical squmous cancer before and after new adujvant chemotherapy treatment （NACT） and to evaluate their relations with tumour chemosensitity. Methods The specimens of 30 cases with cervical squmous cancer before and after NACT are examined by S-P immunohistochemistry. Results （1）P-gp positive expression rate in cervical squmous cancer after NACT is 83.3%, which is significantly higher than that 55.5% before NACT （P〈0.05）; the effective rate is 100% in the case of P-gp negative expression before NACT, which is significantly higher than that of patient with P-gp positive expression 64.1% （P〈0.05）; （2）GST-π positive expression rate in cervical squmous cancer after NACT is 83.3%, which is significantly higher than that 60% before NACT （P〈0.05）; the effective rate of GST-π negative expression before NACT is 83.3%, which is significantly higher than that of patient with GST-π positive expression 66.7%（P〈0.05）. （3）MRP1 positive expression rate in cervical squmous cancer before and after NACT is 86.7% and 93.3%, and there is no significant difference between them （P〉0.05）; the effective rate of patients with MRP1 negative expression before NACT was 100% and positive expression was76.9%,the difference is not significant （P〉0.05）. Conclusion P-pg and GST-π can be used as the predictive markers for the chemosensitivity to NACT in cervical squmous cancer.
出处
《中国医药指南》
2009年第10期41-43,共3页
Guide of China Medicine
基金
兵团医药卫生专项资助课题(项目编号2006GG51)
石河子大学高层次人才科研启动基金(项目编号:RCZX200770)
